GT Biopharma Long Term Debt 2010-2025 | GTBP

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

GT Biopharma long term debt from 2010 to 2025. Long term debt can be defined as the sum of all long term debt fields.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

GT Biopharma long term debt from 2010 to 2025. Long term debt can be defined as the sum of all long term debt fields.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$226.4B
Amgen (AMGN)	$166.3B
Gilead Sciences (GILD)	$141.3B
Vertex Pharmaceuticals (VRTX)	$122.5B
Bristol Myers Squibb (BMY)	$99.7B
CSL (CSLLY)	$85.2B
GSK (GSK)	$77.9B
Regeneron Pharmaceuticals (REGN)	$61.8B
Alnylam Pharmaceuticals (ALNY)	$42.5B
Argenex SE (ARGX)	$35.2B
BioNTech SE (BNTX)	$27.5B
Royalty Pharma (RPRX)	$20.2B
Insmed (INSM)	$19.6B
Biogen (BIIB)	$19.2B
Illumina (ILMN)	$16.6B
Genmab (GNMSF)	$14.9B
Genmab (GMAB)	$14.7B
Incyte (INCY)	$13.7B
Moderna (MRNA)	$13.4B
Exelixis (EXEL)	$12.4B
BioMarin Pharmaceutical (BMRN)	$11.4B
QIAGEN (QGEN)	$11.2B
Swedish Orphan Biovitrum (BIOVF)	$10.6B
Ascendis Pharma (ASND)	$10.4B
Exact Sciences (EXAS)	$9.1B
Verona Pharma American Depositary Share (VRNA)	$8.9B
Bio-Techne Corp (TECH)	$8.7B
Blueprint Medicines (BPMC)	$8.3B
Legend Biotech (LEGN)	$8.1B
Roivant Sciences (ROIV)	$7.7B